Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC. Bachmayr-Heyda A, et al. Among authors: lambrechts s. BMC Cancer. 2013 Sep 17;13:422. doi: 10.1186/1471-2407-13-422. BMC Cancer. 2013. PMID: 24044611 Free PMC article.
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R. Pils D, et al. Among authors: lambrechts s. Eur J Cancer. 2014 Jan;50(1):99-110. doi: 10.1016/j.ejca.2013.09.011. Epub 2013 Oct 28. Eur J Cancer. 2014. PMID: 24176298
Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.
Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I, Mahner S, Lambrechts S, Vergote I, Grimm C, Horvat R, Castillo-Tong DC, Zeillinger R, Pils D. Aust S, et al. Among authors: lambrechts s. Mol Cancer. 2014 Mar 21;13:67. doi: 10.1186/1476-4598-13-67. Mol Cancer. 2014. PMID: 24655477 Free PMC article.
AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.
Svoboda M, Meshcheryakova A, Heinze G, Jaritz M, Pils D, Castillo-Tong DC, Hager G, Thalhammer T, Jensen-Jarolim E, Birner P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Zimmermann P, Zeillinger R, Mechtcheriakova D. Svoboda M, et al. Among authors: lambrechts s. BMC Genomics. 2016 Aug 16;17(1):643. doi: 10.1186/s12864-016-3001-y. BMC Genomics. 2016. PMID: 27527602 Free PMC article.
HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium.
Braicu EI, Luketina H, Richter R, Cacsire Castillo-Tong D, Lambrechts S, Mahner S, Concin N, Mentze M, Zeillinger R, Vergote I, Sehouli J. Braicu EI, et al. Among authors: lambrechts s. Onco Targets Ther. 2014 Sep 11;7:1563-9. doi: 10.2147/OTT.S65373. eCollection 2014. Onco Targets Ther. 2014. PMID: 25246800 Free PMC article.
Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote I. Lambrechts S, et al. Among authors: lambrechts d. Eur J Cancer. 2016 Jan;53:51-64. doi: 10.1016/j.ejca.2015.11.001. Epub 2015 Dec 13. Eur J Cancer. 2016. PMID: 26693899
Corrigendum to "Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer" [Eur J Cancer 53 (2016) 51-64].
Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Castillo-Tong DC, Lambrechts D, Vergote I. Lambrechts S, et al. Among authors: lambrechts d. Eur J Cancer. 2016 Jun;60:226. doi: 10.1016/j.ejca.2016.03.007. Epub 2016 Apr 19. Eur J Cancer. 2016. PMID: 27106403 No abstract available.
Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium.
Obermayr E, Bednarz-Knoll N, Orsetti B, Weier HU, Lambrechts S, Castillo-Tong DC, Reinthaller A, Braicu EI, Mahner S, Sehouli J, Vergote I, Theillet C, Zeillinger R, Brandt B. Obermayr E, et al. Among authors: lambrechts s. Oncotarget. 2017 Nov 16;8(63):106415-106428. doi: 10.18632/oncotarget.22468. eCollection 2017 Dec 5. Oncotarget. 2017. PMID: 29290959 Free PMC article.
Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer.
Meshcheryakova A, Svoboda M, Jaritz M, Mungenast F, Salzmann M, Pils D, Cacsire Castillo-Tong D, Hager G, Wolf A, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Birner P, Zimmermann P, Brindley DN, Heinze G, Zeillinger R, Mechtcheriakova D. Meshcheryakova A, et al. Among authors: lambrechts s. Comput Struct Biotechnol J. 2019 Apr 10;17:537-560. doi: 10.1016/j.csbj.2019.04.004. eCollection 2019. Comput Struct Biotechnol J. 2019. PMID: 31049165 Free PMC article.
116 results